Dosage and formulation
US11000517B2 · kind B2 · utility
0Cited by
81References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 27, 2018 |
| Grant date | May 11, 2021 |
| Priority date | — |
| Expiry date | Jun 27, 2038 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P11/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to pharmaceutical compositions for inhalation comprising aclidinium in the form of a dry powder of a pharmaceutically acceptable salt in admixture with a pharmaceutically acceptable dry powder carrier, providing a metered nominal dose of aclidinium equivalent to about 400 micrograms aclidinium bromide.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.